The goal of radiotherapy is to operate within the therapeutic window - delivering doses of ionizing radiation to achieve locoregional tumour control, while minimizing normal tissue toxicity. A greater therapeutic ratio can be achieved by utilizing radiosensitizing agents designed to enhance the effects of radiation at the tumour. Gold nanoparticles (AuNP) represent a novel radiosensitizer with unique and attractive properties. AuNPs enhance local photon interactions, thereby converting photons into localized damaging electrons. Experimental reports of AuNP radiosensitization reveal this enhancement effect to be highly sensitive to irradiation source energy, cell line, and AuNP size, concentration and intracellular localization. This thesis explored the physics and some of the underlying mechanisms behind AuNP radiosensitization. A Monte Carlo simulation approach was developed to investigate the enhanced photoelectric absorption within AuNPs, and to characterize the escaping energy and range of the photoelectric products. Simulations revealed a 10^3 fold increase in the rate of photoelectric absorption using low-energy brachytherapy sources compared to megavolt sources. For low-energy sources, AuNPs released electrons with ranges of only a few microns in the surrounding tissue. For higher energy sources, longer ranged photoelectric products travelled orders of magnitude farther. A novel radiobiological model called the AuNP radiosensitization predictive (ARP) model was developed based on the unique nanoscale energy deposition pattern around AuNPs. The ARP model incorporated detailed Monte Carlo simulations with experimentally determined parameters to predict AuNP radiosensitization. This model compared well to in vitro experiments involving two cancer cell lines (PC-3 and SK-BR-3), two AuNP sizes (5 and 30 nm) and two source energies (100 and 300 kVp). The ARP model was then used to explore the effects of AuNP intracellular localization using 1.9 and 100 nm AuNPs, and 100 and 300 kVp source energies. The impact of AuNP localization was most significant for low-energy sources. At equal mass concentrations, AuNP size did not impact radiosensitization unless the AuNPs were localized in the nucleus. This novel predictive model of AuNP radiosensitization could help define the optimal use of AuNPs in potential clinical strategies by determining therapeutic AuNP concentrations, and recommending when active approaches to cellular accumulation are most beneficial.

The goal of radiotherapy is to operate within the therapeutic window - delivering doses of ionizing radiation to achieve locoregional tumour control, while minimizing normal tissue toxicity. A greater therapeutic ratio can be achieved by utilizing radiosensitizing agents designed to enhance the effects of radiation at the tumour. Gold nanoparticles (AuNP) represent a novel radiosensitizer with unique and attractive properties. AuNPs enhance local photon interactions, thereby converting photons into localized damaging electrons. Experimental reports of AuNP radiosensitization reveal this enhancement effect to be highly sensitive to irradiation source energy, cell line, and AuNP size, concentration and intracellular localization. This thesis explored the physics and some of the underlying mechanisms behind AuNP radiosensitization. A Monte Carlo simulation approach was developed to investigate the enhanced photoelectric absorption within AuNPs, and to characterize the escaping energy and range of the photoelectric products. Simulations revealed a 10^3 fold increase in the rate of photoelectric absorption using low-energy brachytherapy sources compared to megavolt sources. For low-energy sources, AuNPs released electrons with ranges of only a few microns in the surrounding tissue. For higher energy sources, longer ranged photoelectric products travelled orders of magnitude farther. A novel radiobiological model called the AuNP radiosensitization predictive (ARP) model was developed based on the unique nanoscale energy deposition pattern around AuNPs. The ARP model incorporated detailed Monte Carlo simulations with experimentally determined parameters to predict AuNP radiosensitization. This model compared well to in vitro experiments involving two cancer cell lines (PC-3 and SK-BR-3), two AuNP sizes (5 and 30 nm) and two source energies (100 and 300 kVp). The ARP model was then used to explore the effects of AuNP intracellular localization using 1.9 and 100 nm AuNPs, and 100 and 300 kVp source energies. The impact of AuNP localization was most significant for low-energy sources. At equal mass concentrations, AuNP size did not impact radiosensitization unless the AuNPs were localized in the nucleus. This novel predictive model of AuNP radiosensitization could help define the optimal use of AuNPs in potential clinical strategies by determining therapeutic AuNP concentrations, and recommending when active approaches to cellular accumulation are most beneficial.

Doctor of Philosophy / Department of Biochemistry and Molecular Biophysics / John M. Tomich / Branched Amphiphilic Peptide Capsules (BAPCs) are peptide nano-spheres comprised of equimolar proportions of two branched peptide sequences bis(FLIVI)-K-KKKK and bis(FLIVIGSII)-K-KKKK that self-assemble in water to form bilayer delimited poly-cationic capsules capable of trapping solutes. We examined the lipid-like properties of this system including assembly, fusion, solute encapsulation, and resizing by membrane extrusion as well as their capability to be maintained at a specific size by storage at 4˚C. These studies along with earlier work from the lab (Gudlur et al. (2012) PLOS ONE 7(9): e45374) demonstrated that the capsules, while sharing many properties with lipid vesicles, were much more robust. We next investigated the stability, size limitations of encapsulation, cellular localization, retention and, bio-distribution of the BAPCs. We demonstrated that the BAPCs are readily taken up by epithelial cells in culture, escape or evade the endocytotic pathway, and accumulate in the peri-nuclear region where they persist without any apparent degradation. The stability and persistence of the capsules suggested they might be useful in delivering radionuclides. The BAPCs encapsulated alpha particle emitting radionuclides without any apparent leakage, were taken up by cells and were retained for extended periods of time. Their potential in this clinical application is being currently pursued. Lastly we studied the temperature dependence of capsule formation by examining the biophysical characteristics of temperature induced conformational changes in BAPCs and examined the structural parameters within the sequences that contribute to their remarkable stability. A region in the nine-residue sequence was identified as the critical element in this process. The ability to prepare stable uniform nano-scale capsules of desired sizes makes BAPCs potentially attractive as delivery vehicles for various solutes/drugs.

Depuis le début des années soixante-dix, le nombre de scanners par hôpitaux n’a fait qu’augmenter et leur utilisation est de plus en plus fréquente. Même si cette technique permet de donner des informations cliniques précieuses, elle a un revers qui est l’exposition du patient à des rayonnements ionisants. La sensibilité des enfants aux rayonnements est plus grande que celle des adultes, les enfants ont une espérance de vie importante et ont donc plus de risques de développer des cancers dans le futur. Il y a donc nécessité de tenter de réduire la dose au patient. Cette thèse vise donc à développer des stratégies d’optimisation sur les protocoles cliniques en utilisant des méthodes de simulation et de modélisation permettant de comprendre l’influence des paramètres des protocoles sur les indicateurs de qualité d’image et sur la dose délivrée au patient. Ce travail se divise en quatre parties: La première partie porte sur la modélisation de l’influence des paramètres des protocoles scanographiques sur deux indicateurs de qualité d’image et un indicateur de dose en utilisant la méthodologie des plans d’expériences. La seconde partie traite du développement d’un Protocole Générique Optimisé (PGO) pour la région de l’abdomen. A partir des données des modèles développés, un PGO recalculé pour cinq morphologies de patients pédiatriques et pour quatre modèles de scanners a été réalisé. L’ensemble des résultats, ont permis le développement d’un outil d’aide à l’optimisation permettant à l’utilisateur de générer un protocole optimisé en fonction du modèle de scanner et de la morphologie du patient. / For the last 10-years, computed tomography (CT) procedures and their increased use have been a major source for concern in the scientific community. This concern has been the starting point for several studies aiming to optimize the dose while maintaining a diagnostic image quality. In addition, it is important to pay special attention to dose levels for children (age range considered to be from a newborn baby to a 16-y-old patient). Indeed, children are more sensitive to ionizing radiations, and they have a longer life expectancy. Optimizing the CT protocols is a very difficult process due to the complexity of the acquisition parameters, starting with the individual patient characteristics, taking into account the available CT device and the required diagnostic image quality. This PhD project is contributing to the advancement of knowledge by: (1) Developing a new approach that can minimize the number of testing CT scans examinations while developing a predictive mathematical model allowing radiologists to prospectively anticipate how changes in protocols will affect the image quality and the delivered dose for four models of CT scan. (2) Setting-up a Generic Optimized Protocol (based on the size of the phantom CATPAHN 600) for four models of CT scan. (3) Developing a methodology to adapt the GOP to five sizes of pediatric patient using Size Specific Dose Estimate calculation (SSDE). (4) Evaluating subjective and objective image quality between size-based optimised CT protocol and age-based CT protocols. (5) Developing a CT protocol optimization tool and a tutorial helping the radiologists in the process of optimization.

The overexpression of the human epidermal growth factor receptor-2 (HER-2) in 20-25% of human breast cancers was investigated as a target for development of a gold nanoparticle (AuNP) based radiosensitizer for improving the efficacy of neoadjuvant X-radiation therapy of the disease. HER-2 targeted AuNPs were developed by covalently conjugating trastuzumab, a Health Canada approved monoclonal antibody for the treatment of HER-2-overexpressing breast cancer, to 30 nm AuNPs. Trastuzumab conjugated AuNPs were efficiently internalized by HER-2-overexpressing breast cancer cells (as assessed by darkfield microscopy and transmission electron microscopy) and increased DNA damage from X-radiation in these cells by more than 5-fold. To optimize delivery of AuNPs to HER-2-overexpressing tumors, high resolution microSPECT/CT imaging was used to track the in vivo fate of 111In-labelled non-targeted and HER-2 targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and non-specific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to non-targeted AuNPs. This phenomenon could be attributed to Fc-mediated recognition and subsequent sequestration of trastuzumab conjugated AuNP by the reticuloendothelial system (RES). Blocking of the RES did not increase tumor uptake of either HER-2 targeted or non-targeted AuNPs. Following i.t. injection, our results suggest that Au-NTs redistribute over time and traffick to the liver via the ipsilateral axillary lymph node leading to comparable exposure as seen with i.v. administration. In contrast, targeted AuNPs are bound and internalized by HER-2-overexpressing tumor cells following i.t. injection, with a lower proportion of AuNPs redistributing to normal tissues. In vivo, the combination of HER-2 targeted AuNPs injected i.t. and X-radiation (11 Gy) yielded a 46% decrease in tumor size over a 4 month period in contrast to an 11.5% increase in tumor size for X-radiation treatment alone. Toxicology studies (evaluated through complete blood cell counts, by serum transaminase and creatinine measurements and by monitoring the body weight) demonstrated no apparent normal organ toxicity from the combination of HER-2 targeted AuNPs and X-radiation. These results are promising for the clinical translation of HER-2-targeted AuNPs for radiosensitization of tumors to X-radiation.

The overexpression of the human epidermal growth factor receptor-2 (HER-2) in 20-25% of human breast cancers was investigated as a target for development of a gold nanoparticle (AuNP) based radiosensitizer for improving the efficacy of neoadjuvant X-radiation therapy of the disease. HER-2 targeted AuNPs were developed by covalently conjugating trastuzumab, a Health Canada approved monoclonal antibody for the treatment of HER-2-overexpressing breast cancer, to 30 nm AuNPs. Trastuzumab conjugated AuNPs were efficiently internalized by HER-2-overexpressing breast cancer cells (as assessed by darkfield microscopy and transmission electron microscopy) and increased DNA damage from X-radiation in these cells by more than 5-fold. To optimize delivery of AuNPs to HER-2-overexpressing tumors, high resolution microSPECT/CT imaging was used to track the in vivo fate of 111In-labelled non-targeted and HER-2 targeted AuNPs following intravenous (i.v.) or intratumoral (i.t.) injection. For i.v. injection, the effects of GdCl3 (for deactivation of macrophages) and non-specific (anti-CD20) antibody rituximab (for blocking of Fc mediated liver and spleen uptake) were studied. It was found that HER-2 targeting via attachment of trastuzumab paradoxically decreased tumor uptake as a result of faster elimination of the targeted AuNPs from the blood while improving internalization in HER-2-positive tumor cells as compared to non-targeted AuNPs. This phenomenon could be attributed to Fc-mediated recognition and subsequent sequestration of trastuzumab conjugated AuNP by the reticuloendothelial system (RES). Blocking of the RES did not increase tumor uptake of either HER-2 targeted or non-targeted AuNPs. Following i.t. injection, our results suggest that Au-NTs redistribute over time and traffick to the liver via the ipsilateral axillary lymph node leading to comparable exposure as seen with i.v. administration. In contrast, targeted AuNPs are bound and internalized by HER-2-overexpressing tumor cells following i.t. injection, with a lower proportion of AuNPs redistributing to normal tissues. In vivo, the combination of HER-2 targeted AuNPs injected i.t. and X-radiation (11 Gy) yielded a 46% decrease in tumor size over a 4 month period in contrast to an 11.5% increase in tumor size for X-radiation treatment alone. Toxicology studies (evaluated through complete blood cell counts, by serum transaminase and creatinine measurements and by monitoring the body weight) demonstrated no apparent normal organ toxicity from the combination of HER-2 targeted AuNPs and X-radiation. These results are promising for the clinical translation of HER-2-targeted AuNPs for radiosensitization of tumors to X-radiation.

La tomographie par émission de positons (TEP) est une modalité d’imagerie nucléaire puissante, permettant des mesures fonctionnelles non-invasive dans les cellules, les animaux et les humains avec une haute sensibilité et résolution. Les exosomes sont des vésicules extracellulaires de 30 à 120 nm qui peuvent transférer leur contenu cytoplasmique entre cellules, mais comprendre leurs cheminements in vivo reste un défi. Les hydrogels thermosensibles à base de chitosane ont été développés et sont sous optimisation pour diverses applications telles que l'embolisation des vaisseaux sanguins, l'administration de médicaments, l’'administration de lymphocytes et la réparation du cartilage et des disques intervertébraux. Il y a un besoin urgent de suivi in vivo à court terme pour évaluer la rétention des hydrogels et des exosomes. Le Hexadécyl-4- [18F]-fluorobenzoate ([18F]HFB) est un radiotraceur lipophile à longue chaîne qui est retenu dans les membranes cellulaires et les biomatériaux. Le but de ce travail était d'automatiser la radiosynthèse de [18F]HFB pour marquer des exosomes et des hydrogels. La radiosynthèse et la purification de [18F]HFB ont été réalisées en utilisant le synthétiseur de chimie commercial IBA Synthera®. [18F]HFB a été préparé via substitution du précurseur d’ammonium quaternaire par [18F]F-. Après une première purification via une cartouche C18, [18F]HFB a été élué avec de l'acétonitrile et purifié par HPLC. [18F]HFB a ensuite été reformulé dans une solution de DMSO (10%) après élimination du solvant HPLC sous azote, filtré et dilué dans une solution saline stérile. [18F]HFB a été obtenu en rendement radiochimique allant de 15 à 45% (corrigé pour désintégration), en haute pureté radiochimique et chimique, et dans un temps de synthèse total de 60 minutes. Les exosomes n'ont pas été marqués avec succès. Cependant, les hydrogels de chitosane ont démontré un marquage élevé, avec une stabilité du complexe >90%, même après 8 heures d’incubation en solution saline. La TEP avec [18F]HFB d'exosomes et de biomatériaux présente une approche novatrice pour déterminer leur distribution in vivo. / Positron emission tomography (PET) is a powerful nuclear imaging modality allowing for non-invasive functional measures in cells, animals and humans with high sensitivity. Exosomes are 30-120 nm extracellular vesicles that can transfer their cytoplasmic contents between cells, however, understanding where exosomes traffic in the body remains a challenge. Chitosan-based thermosensitive hydrogels have been developed and are currently under optimization for various applications such as blood vessel embolization, drug delivery, lymphocyte delivery systems, and cartilage and intervertebral disc repair. There is an urgent need for in vivo, short term follow-up of such procedures to assess the retention of hydrogels and exosomes at the site of injection. Hexadecyl-4-[18F]fluorobenzoate ([18F]HFB) is a long chain lipophilic radiotracer that has been reported to be retained within cell membranes or biomaterials. The aim of this work was to automate the radiosynthesis of [18F]HFB for labeling exosomes and chitosan-based hydrogels. The radiosynthesis and purification of [18F]HFB was done using the commercial IBA Synthera® chemistry synthesiser with the R&D IFP-cassette and HPLC module. As previously reported, [18F]HFB was prepared by [18F]F- substitution of the trimethyl ammonium triflate precursor in DMSO. After removal of unreacted [18F]F- and DMSO via a C18 light cartridge, [18F]HFB was eluted with acetonitrile and purified by semi-prep C18 HPLC. [18F]HFB was then reformulated in DMSO (10%) solution after removal of the HPLC solvent from the radioactive product peak under nitrogen, filtered, and diluted in sterile saline. [18F]HFB was obtained in radiochemical yield (isolated after HPLC and evaporation) ranging from 15 – 45% (decay-corrected), high radiochemical and chemical purities, and within a total synthesis time of 60 mins. Exosomes were not successfully labeled. However, high labeling efficiency was observed with the chitosan hydrogels displaying a stability >90%, even after 8 hours incubation in saline. PET imaging with [18F]HFB of exosomes and biomaterials presents a novel approach to determining their in vivo distribution.